HBT Labs
HBT Labs is a privately held pharmaceutical manufacturer (founded 2013, Brea, CA, 11-50 employees) that produces FDA-approved injectable medications including epinephrine, iron sucrose, and sodium phosphates for hospitals, clinics, and veterinary practices, distributing through an American Regent / Daiichi Sankyo affiliated network.
- Company typePrivate
- Founded2013
- HeadquartersBrea, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What HBT Labs does
HBT Labs is a privately held pharmaceutical company founded in 2013 and headquartered in Brea, California, with 11-50 employees. The company manufactures and supplies complex injectable medications — including epinephrine, iron sucrose (Venofer), sodium phosphates, potassium phosphates, zinc sulfate, and other FDA-approved formulations — for human and veterinary healthcare applications. Its core technology is pharmaceutical injectable manufacturing, a highly regulated discipline requiring FDA approval and complex formulation capabilities.
The company serves healthcare providers, hospitals, clinics, healthcare facilities, and veterinary practices, distributing products through an authorized pharmaceutical distributor network affiliated with American Regent, a Daiichi Sankyo Group Company. This affiliation provides access to global pharmaceutical expertise, distribution infrastructure, and a broader product portfolio than HBT Labs could independently support. The company also maintains an animal health product line via AR Animal Health.
HBT Labs operates a B2B pharmaceutical distribution model with non-publicly disclosed pricing, selling through authorized distributors with direct customer service support for healthcare facilities. No revenue, funding, or ownership details are publicly disclosed. The company is led by co-founder and president Don Hodgson and COO Janet Braun. The relationship between HBT Labs and American Regent — whether subsidiary, contract manufacturer, or affiliated entity — is not explicitly defined in available sources, though product and channel overlap is substantial.
HBT Labs firmographics
Firmographics- Name
- HBT Labs
- Website
- https://hbt-labs.com
- Company type
- Private
- Founded year
- 2013
- Headcount range
- 11–50 employees
- Short description
- HBT Labs is a privately held pharmaceutical manufacturer (founded 2013, Brea, CA, 11-50 employees) that produces FDA-approved injectable medications including epinephrine, iron sucrose, and sodium phosphates for hospitals, clinics, and veterinary practices, distributing through an American Regent / Daiichi Sankyo affiliated network.
- Ownership category
- akta.pro rank
HBT Labs industry classification
Industry- Product category
- Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)
Keywords
Where HBT Labs is headquartered
LocationHeadquarters
- HQ city
- Brea
- HQ country
- United States
- HQ region
- North America
Markets served
HBT Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain
Distribution channels1 record
HBT Labs product offering
Product offeringCore offering
HBT Labs manufactures and supplies complex injectable pharmaceutical drugs—including epinephrine, iron sucrose, and sodium phosphates injections—based on advanced technology. The products are sold to hospitals, clinics, healthcare facilities, and veterinary practices for patient treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- Epinephrine Injection Injectable epinephrine formulation used for patient treatment in hospitals, clinics, and healthcare facilities.
- Iron Sucrose Injection Iron sucrose injectable formulation for patient treatment, supplied to healthcare providers.
- Sodium Phosphates Injection Sodium phosphates injectable formulation for patient treatment, distributed to hospitals, clinics, and veterinary practices.
Companies that use HBT Labs
Customer profileSegments1 record
Ideal customer profiles1 record
HBT Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HBT Labs partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
HBT Labs competitors and assessment
Company assessmentBroad incumbents
- Fresenius Kabi: Global specialty/generic injectable and infusion therapy manufacturer competing across the same hospital injectable categories (iron, electrolytes, anesthesia) as HBT Labs, with broader portfolio and geographic reach.
- B. Braun: Major manufacturer of sterile injectable solutions, IV drugs, and infusion supplies serving hospitals and clinics in the U.S., with overlapping products such as sodium phosphates and IV fluids.
- Baxter International: Global hospital products manufacturer supplying injectable solutions, IV drugs, and anesthesia products into the same hospital channels as HBT Labs, including competing injectable electrolytes.
- Pfizer (Hospira): Through Hospira, Pfizer is a leading global injectable pharmaceutical manufacturer with a portfolio that overlaps HBT Labs in hospital injectables, offering both broad scale and brand recognition.
Direct peers
- American Regent: Daiichi Sankyo Group Company that manufactures and distributes injectable pharmaceuticals including Venofer, Injectafer, and Gvoke. Operationally intertwined with HBT Labs and the most direct comparison given shared product set and customer base.
- Eugia US (Aurobindo): U.S. specialty injectable arm of Aurobindo Pharma marketing a wide range of sterile injectables in oncology, anti-infectives, and critical care, competing directly with HBT Labs' hospital channel offerings.
- Hikma Pharmaceuticals: U.S. injectables business (Hikma Injectables) markets a broad portfolio of generic sterile injectables including anti-infectives, oncology, and cardiovascular products sold into hospitals through similar distribution channels.
- Sagent Pharmaceuticals: Specialty generic injectable company focused on hospital and surgical injectables, with overlapping molecules such as heparin, anti-infectives, and cardiovascular injectables.
- Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company with a portfolio including epinephrine, enoxaparin, and other hospital injectables, competing head-to-head with HBT Labs in several core SKUs.
Emerging players
- WG Critical Care: U.S. specialty injectable company focused on hospital essential medicines including sodium phosphates, electrolytes, and critical care injectables that overlap with HBT Labs' core portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
HBT Labs social profiles
Digital presenceHBT Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
HBT Labs leadership team
Management profileNumber of profiles
Profiles2 records
HBT Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HBT Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HBT Labs
What does HBT Labs do?
HBT Labs manufactures and supplies complex injectable pharmaceutical drugs—including epinephrine, iron sucrose, and sodium phosphates injections—based on advanced technology. The products are sold to hospitals, clinics, healthcare facilities, and veterinary practices for patient treatment.
When was HBT Labs founded?
HBT Labs was founded in 2013. It employs 11 to 50 people.
Where is HBT Labs based?
HBT Labs is headquartered in Brea, United States, in the North America region.
Who are HBT Labs's main competitors?
Broad incumbents on record are Fresenius Kabi, B. Braun, Baxter International and Pfizer (Hospira). Direct peers are American Regent, Eugia US (Aurobindo), Hikma Pharmaceuticals, Sagent Pharmaceuticals and Amphastar Pharmaceuticals. WG Critical Care is listed as an emerging player.
Does HBT Labs have an API?
No public API is recorded for HBT Labs.
What industry is HBT Labs in?
HBT Labs's product category is Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAMAEAF, Pain Management, Anesthesia & Critical Care Drugs. Its NAICS code is 325412 and its SIC code is 2834.